Stay updated with breaking news from Trial Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the... | June 11, 2023
Dupixent® late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic for... | June 11, 2023
FinancialContent fully hosted finance channel
Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial ProgramKANSAS CITY, Kan., May 03, 2023 -- Cingulate Inc. ,... | May 3, 2023
Cingulate Announces Successful Transfer of CTx-1301 Proprietary PTR™ Manufacturing Processes to Societal CDMO Scalable Supply of CTx-1301 Ready to be... | May 3, 2023